Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) plans to separate its MRD and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine and expects to determine a preferred separation path by year-end 2026.
MRD has scaled into a profitable, category-leading diagnostics business with expanded reimbursement, strong clinical evidence, and the clonoSEQ platform. Immune Medicine has built a differentiated discovery platform using a large clinically linked immune receptor dataset and AI-driven discovery.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- MRD scaled to profitability with expanded reimbursement
- clonoSEQ established as a leading MRD testing platform
- Immune Medicine built a uniquely differentiated discovery platform
- Largest clinically linked immune receptor dataset supports discovery
- AI-driven discovery platform shows potential for precision medicines
- Planned separation intended to unlock value for both businesses
Negative
- Separation structure for Immune Medicine not yet determined
- Timeline only targets preferred path decision by year-end 2026
News Market Reaction – ADPT
On the day this news was published, ADPT declined 1.37%, reflecting a mild negative market reaction. Argus tracked a trough of -19.2% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $39M from the company's valuation, bringing the market cap to $2.82B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 29 | MRD data updates | Positive | -0.3% | New clonoSEQ MRD data featured in 33 ASCO and EHA presentations. |
| May 21 | Investor conferences | Neutral | +0.1% | Announcement of participation in two investor conferences and webcasts. |
| May 05 | Q1 2026 earnings | Positive | +4.7% | Strong MRD-led revenue growth and raised full-year MRD guidance. |
| Apr 15 | Earnings date notice | Neutral | -3.1% | Scheduled timing and webcast details for upcoming Q1 2026 results. |
| Feb 05 | FY 2025 earnings | Positive | -4.3% | Strong 2025 revenue growth and MRD profitability with higher test volumes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings with strong MRD growth have previously seen positive reactions, while several other positive or neutral announcements, including major MRD data and full-year results, were followed by modest to notable declines.
Over the past six months, Adaptive Biotechnologies has highlighted MRD-driven growth and increasing clinical adoption. Q4 2025 and Q1 2026 earnings showed strong MRD revenue and rising clonoSEQ volumes, but price reactions were mixed, with a +4.72% move on Q1 2026 versus a -4.25% move on 2025 results. Scientific updates at ASCO/EHA 2026 and conference participation produced minimal price impact. Today’s plan to separate the MRD and Immune Medicine businesses follows earlier disclosures that MRD is driving scale and profitability while Immune Medicine remains a distinct discovery platform.
Regulatory & Risk Context
Key Terms
minimal residual disease medical
mrd medical
ai-driven discovery technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by year-end 2026.
Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both businesses have continued to advance. MRD has achieved significant scale, expanded reimbursement, strengthened its clinical evidence base and reached profitability, establishing clonoSEQ® as a leading platform in MRD testing.
At the same time, Immune Medicine has continued to build a uniquely differentiated discovery platform anchored by the world's largest clinically linked immune receptor dataset and enhanced by advances in AI-driven discovery. The platform is increasingly demonstrating its potential to generate novel biological insights, identify therapeutic targets, and accelerate the development of precision medicines. As Immune Medicine enters its next phase of growth, the company believes the value of its differentiated assets may be best realized outside of a diagnostic commercial model.
"When we completed our strategic review in 2024, we decided to continue developing both MRD and Immune Medicine within Adaptive while increasing their operational independence," said Chad Robins, Chief Executive Officer and Co-Founder of Adaptive Biotechnologies. "The progress achieved by both businesses has reinforced that decision. As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive. We believe this separation is the best way to unlock the full potential of both businesses, increasing their impact on patients and creating long-term value for shareholders."
About the MRD business
Adaptive’s MRD business has achieved significant scale, profitability and expanded clinical utility. Revenue has grown from
About the Immune Medicine business
Immune Medicine has progressed its data and drug discovery capabilities to uncover causal immune drivers to enable precision medicine in autoimmune diseases. With over 6 million functional T-cell receptor (TCR)-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the disease-causing antigens they bind.
There can be no assurance that this process will result in any transaction or other outcome, or as to the timing or terms of any such transaction. Adaptive does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or required.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding Adaptive’s business strategies, strategic focus, review of strategic alternatives for Immune Medicine, potential sale, separation, partnership, licensing transaction or other strategic or operational outcome involving Immune Medicine, the timing and outcome of any strategic review process, the growth, profitability, reimbursement, clinical adoption and commercial opportunity of the MRD business, the market opportunity for clonoSEQ, expected margin expansion, disciplined capital allocation, company-wide profitability and plans and objectives for future operations.
In some cases, forward-looking statements can be identified by words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “focus,” “opportunity,” “evaluate,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents Adaptive files with the Securities and Exchange Commission from time to time. Adaptive cautions that forward-looking statements are based on a combination of facts and factors currently known to the company and projections of the future, about which Adaptive cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Adaptive’s views as of the date hereof. Adaptive undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
